{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T04:29:48Z","timestamp":1794889788425,"version":"4.9.1"},"reference-count":38,"publisher":"American Society of Hematology","issue":"3","license":[{"start":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>In acute myeloid leukemia (AML), donor natural killer cell killer immunoglobulin\u2013like receptors (KIR) and recipient HLA interactions may contribute to the graft-versus-leukemia effect of allogeneic hematopoietic cell transplantation (HCT). Analyses of individual KIR\/HLA interactions, however, have yielded conflicting findings, and their importance in the HLA-matched unrelated donor (MUD) setting remains controversial. We systematically studied outcomes of individual donor-KIR\/recipient-HLA interactions for HCT outcomes and empirically evaluated prevalent KIR genotypes for clinical benefit. Adult patients with AML (n\u00a0= 2025) who received HCT with MUD grafts in complete remission reported to the Center for International Blood and Marrow Transplantation were evaluated. Only the donor-2DL2+\/recipient-HLA-C1+ pair was associated with reduced relapse (hazard ratio [HR], 0.79; 95% confidence interval [CI], 0.67-0.93; P\u00a0= .006) compared with donor-2DL2\u2013\/recipient-HLA-C1+ pair. However, no association was found when comparing HLA-C groups among KIR-2DL2+\u2013graft recipients. We identified 9 prevalent donor KIR genotypes in our cohort and screened them for association with relapse risk. Genotype 5 (G5) in all recipients and G3 in Bw4+ recipients were associated with decreased relapse risk (HR, 0.52; 95%\u00a0CI, 0.35-0.78; P\u00a0= .002; and HR, 0.32; 95%\u00a0CI, 0.14-0.72; P\u00a0= .006; respectively) and G2 (HR 1.63, 95%\u00a0CI, 1.15-2.29; P\u00a0= .005) with increased relapse risk in C1-homozygous recipients, compared with other patients with the same ligand. However, we could not validate these findings in an external data set of 796 AML transplants from the German transplantation registry. Neither a systematic evaluation of known HLA-KIR interactions nor an empiric assessment of prevalent KIR genotypes demonstrated clinically actionable associations; therefore, these data do not support these KIR-driven strategies for MUD selection in AML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011622","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T17:05:55Z","timestamp":1701795955000},"page":"581-590","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["Systematic evaluation of donor-KIR\/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AML"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5441-1516","authenticated-orcid":false,"given":"Joshua A.","family":"Fein","sequence":"first","affiliation":[{"name":"1Depatment of Hematology and Medical Oncology, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9827-8032","authenticated-orcid":false,"given":"Roni","family":"Shouval","sequence":"additional","affiliation":[{"name":"2Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8728-3327","authenticated-orcid":false,"given":"Elizabeth","family":"Krieger","sequence":"additional","affiliation":[{"name":"3Children\u2019s Hospital of Richmond, Virginia Commonwealth University, Richmond, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Spellman","sequence":"additional","affiliation":[{"name":"4Center for International Blood and Marrow Transplant Research, National Marrow Donor Program\/Be The Match, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2596-6843","authenticated-orcid":false,"given":"Tao","family":"Wang","sequence":"additional","affiliation":[{"name":"4Center for International Blood and Marrow Transplant Research, National Marrow Donor Program\/Be The Match, Minneapolis, MN"},{"name":"5Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Baldauf","sequence":"additional","affiliation":[{"name":"6Clinical Trials Unit, DKMS Bone Marrow Registry, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5827-8000","authenticated-orcid":false,"given":"Katharina","family":"Fleischhauer","sequence":"additional","affiliation":[{"name":"7Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-9966","authenticated-orcid":false,"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[{"name":"8Department of Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Horowitz","sequence":"additional","affiliation":[{"name":"5Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0198-2064","authenticated-orcid":false,"given":"Martin","family":"Maiers","sequence":"additional","affiliation":[{"name":"4Center for International Blood and Marrow Transplant Research, National Marrow Donor Program\/Be The Match, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S","family":"Miller","sequence":"additional","affiliation":[{"name":"9Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Saint Antoine Hospital, Sorbonne University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0763-1265","authenticated-orcid":false,"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[{"name":"11Division of Hematoloy, Chaim Sheba Medical Center, Tel HaShomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8078-8579","authenticated-orcid":false,"given":"Daniel","family":"Weisdorf","sequence":"additional","affiliation":[{"name":"9Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8718-9373","authenticated-orcid":false,"given":"Karl-Johan","family":"Malmberg","sequence":"additional","affiliation":[{"name":"12Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5317-8433","authenticated-orcid":false,"given":"Amir A.","family":"Toor","sequence":"additional","affiliation":[{"name":"13Topper Cancer Institute, Lehigh Valley Health Network, Allentown, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2780-2981","authenticated-orcid":false,"given":"Johannes","family":"Schetelig","sequence":"additional","affiliation":[{"name":"6Clinical Trials Unit, DKMS Bone Marrow Registry, T\u00fcbingen, Germany"},{"name":"14Medizinische Klinik I, University Hospital TU Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9077-4736","authenticated-orcid":false,"given":"Rizwan","family":"Romee","sequence":"additional","affiliation":[{"name":"15Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Koreth","sequence":"additional","affiliation":[{"name":"15Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"issue":"8","key":"2024021217050568100_bib1","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/leu.2017.79","article-title":"Alloreactivity: the Janus-face of hematopoietic stem cell transplantation","volume":"31","author":"Gratwohl","year":"2017","journal-title":"Leukemia"},{"issue":"5562","key":"2024021217050568100_bib2","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"issue":"9","key":"2024021217050568100_bib3","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1056\/NEJMoa1200503","article-title":"HLA-C\u2013dependent prevention of leukemia relapse by donor activating KIR2DS1","volume":"367","author":"Venstrom","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2024021217050568100_bib4","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood-2008-07-171926","article-title":"Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia","volume":"113","author":"Cooley","year":"2009","journal-title":"Blood"},{"issue":"10","key":"2024021217050568100_bib5","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1182\/blood-2017-08-752170","article-title":"Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation","volume":"131","author":"Cooley","year":"2018","journal-title":"Blood"},{"issue":"16","key":"2024021217050568100_bib6","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1182\/blood.2019002887","article-title":"External validation of models for KIR2DS1\/KIR3DL1-informed selection of hematopoietic cell donors fails","volume":"135","author":"Schetelig","year":"2020","journal-title":"Blood"},{"key":"2024021217050568100_bib7","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fimmu.2020.02022","article-title":"Influence of KIR and NK cell reconstitution in the outcomes of hematopoietic stem cell transplantation","volume":"11","author":"Gao","year":"2020","journal-title":"Front Immunol"},{"issue":"4","key":"2024021217050568100_bib8","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.bbmt.2019.10.016","article-title":"Killer Immunoglobulin-like receptor-ligand interactions predict clinical outcomes following unrelated donor transplantations","volume":"26","author":"Krieger","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2024021217050568100_bib9","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1038\/s41409-021-01393-9","article-title":"Increased donor inhibitory KIR with known HLA interactions provide protection from relapse following HLA matched unrelated donor HCT for AML","volume":"56","author":"Krieger","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2024021217050568100_bib10","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-020711-075005","article-title":"controlling natural killer cell responses: integration of signals for activation and inhibition","volume":"31","author":"Long","year":"2013","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"2024021217050568100_bib11","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1182\/bloodadvances.2019001053","article-title":"KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation","volume":"4","author":"Weisdorf","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2024021217050568100_bib12","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/j.bbmt.2018.08.022","article-title":"KIR donor selection: feasibility in identifying better donors","volume":"25","author":"Weisdorf","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2024021217050568100_bib13","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1046\/j.1365-2141.1997.1112925.x","article-title":"IBMTR severity index for grading acute graft-versus-host-disease: retrospective comparison with Glucksberg scale","volume":"97","author":"Rowlings","year":"1997","journal-title":"Br J Haematol"},{"issue":"14","key":"2024021217050568100_bib14","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1182\/blood-2010-05-283051","article-title":"Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia","volume":"116","author":"Cooley","year":"2010","journal-title":"Blood"},{"key":"2024021217050568100_bib15","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-1-4757-3294-8_6","volume-title":"Testing proportional hazards. Modeling Survival Data: Extending the Cox Model. Statistics for Biology and Health","author":"Therneau","year":"2000"},{"issue":"6","key":"2024021217050568100_bib16","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2009-09-245746","article-title":"Education of human natural killer cells by activating killer cell immunoglobulin-like receptors","volume":"115","author":"Fauriat","year":"2010","journal-title":"Blood"},{"issue":"database issue","key":"2024021217050568100_bib17","doi-asserted-by":"crossref","first-page":"D913","DOI":"10.1093\/nar\/gkq1128","article-title":"Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations","volume":"39","author":"Gonzalez-Galarza","year":"2011","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"2024021217050568100_bib18","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.bbmt.2015.05.002","article-title":"Impact of KIR and HLA genotypes on outcomes after reduced-intensity conditioning hematopoietic cell transplantation","volume":"21","author":"Sobecks","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"2024021217050568100_bib19","first-page":"2268","article-title":"KIR3DL1\/HLA-B subtypes govern acute myelogenous leukemia relapse after hematopoietic cell transplantation","volume":"35","author":"Boudreau","year":"2017","journal-title":"J\u00a0Clin Orthod"},{"issue":"7","key":"2024021217050568100_bib20","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/bloodadvances.2019001284","article-title":"Investigation of donor KIR content and matching in children undergoing hematopoietic cell transplantation for acute leukemia","volume":"4","author":"Verneris","year":"2020","journal-title":"Blood Adv"},{"key":"2024021217050568100_bib21","doi-asserted-by":"crossref","first-page":"584520","DOI":"10.3389\/fimmu.2020.584520","article-title":"Haplotype motif-based models for KIR-genotype informed selection of hematopoietic cell donors fail to predict outcome of patients with myelodysplastic syndromes or secondary acute myeloid leukemia","volume":"11","author":"Schetelig","year":"2020","journal-title":"Front Immunol"},{"issue":"7","key":"2024021217050568100_bib22","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/bloodadvances.2020002701","article-title":"Prospective KIR genotype evaluation of hematopoietic cell donors is feasible with potential to benefit patients with AML","volume":"5","author":"Shaffer","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"2024021217050568100_bib23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/bmt.2008.432","article-title":"KIR genes and KIR ligands affect occurrence of acute GVHD after unrelated, 12\/12 HLA matched, hematopoietic stem cell transplantation","volume":"44","author":"Ludajic","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"15","key":"2024021217050568100_bib24","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1182\/blood-2009-08-236943","article-title":"Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation","volume":"115","author":"Venstrom","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2024021217050568100_bib25","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/01.TP.0000137103.19717.86","article-title":"increased infection-related mortality in kir-ligand\u2013mismatched unrelated allogeneic hematopoietic stem-cell transplantation","volume":"78","author":"Schaffer","year":"2004","journal-title":"Transplantation"},{"issue":"4","key":"2024021217050568100_bib26","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.molimm.2004.07.037","article-title":"KIR-ligand mismatch in allogeneic hematopoietic stem cell transplantation","volume":"42","author":"Malmberg","year":"2005","journal-title":"Mol Immunol"},{"issue":"3","key":"2024021217050568100_bib27","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.bbmt.2008.11.030","article-title":"The effect of single and combined activating killer immunoglobulin-like receptor genotypes on cytomegalovirus infection and immunity after hematopoietic cell transplantation","volume":"15","author":"Zaia","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2024021217050568100_bib28","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.bbmt.2010.02.024","article-title":"Decreased infections in recipients of unrelated donor hematopoietic cell transplantation from donors with an activating KIR genotype","volume":"16","author":"Tomblyn","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2024021217050568100_bib29","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1089\/aid.2006.0165","article-title":"Lack of KIR3DS1 binding to MHC class I Bw4 tetramers in complex with CD8+ T cell epitopes","volume":"23","author":"Gillespie","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"1","key":"2024021217050568100_bib30","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bbmt.2013.10.017","article-title":"donor selection for killer immunoglobulin-like receptors B haplotype of the centromeric motifs can improve the outcome after HLA-identical sibling hematopoietic stem cell transplantation","volume":"20","author":"Zhou","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2024021217050568100_bib31","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.4049\/jimmunol.2100119","article-title":"Following transplantation for acute myelogenous leukemia, donor KIR Cen B02 better protects against relapse than KIR Cen B01","volume":"206","author":"Guethlein","year":"2021","journal-title":"J\u00a0Immunol"},{"issue":"suppl 1","key":"2024021217050568100_bib32","first-page":"16","article-title":"Segregation of high-resolution B haplotypes points toward protective donor KIR genotypes after unrelated stem cell transplantation for patients with AML or MDS","volume":"57","author":"Schetelig","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2024021217050568100_bib33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.it.2009.01.006","article-title":"NK cell education: not an on-off switch but a tunable rheostat","volume":"30","author":"Brodin","year":"2009","journal-title":"Trends Immunol"},{"issue":"5","key":"2024021217050568100_bib34","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/ni1581","article-title":"Up on the tightrope: natural killer cell activation and inhibition","volume":"9","author":"Lanier","year":"2008","journal-title":"Nat Immunol"},{"issue":"11","key":"2024021217050568100_bib35","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1182\/blood-2008-05-156836","article-title":"The strength of inhibitory input during education quantitatively tunes the functional responsiveness of individual natural killer cells","volume":"113","author":"Brodin","year":"2009","journal-title":"Blood"},{"issue":"9","key":"2024021217050568100_bib36","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/bloodadvances.2022008863","article-title":"Shared graft-versus-leukemia minor histocompatibility antigens in DISCOVeRY-BMT","volume":"7","author":"Olsen","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"2024021217050568100_bib37","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S2352-3026(20)30394-X","article-title":"Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry","volume":"8","author":"Shouval","year":"2021","journal-title":"Lancet Haematol"},{"issue":"25","key":"2024021217050568100_bib38","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N\u00a0Engl J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/3\/581\/2212937\/blooda_adv-2023-011622-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/3\/581\/2212937\/blooda_adv-2023-011622-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T12:05:51Z","timestamp":1707739551000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/3\/581\/506507\/Systematic-evaluation-of-donor-KIR-recipient-HLA"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,2,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011622","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,25]]}}}